clinical trial · NCT07308574
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Alexion Pharmaceuticals, Inc.·phase4·recruiting·n = 20
aHUSAtypical Hemolytic Uremic SyndromeRavulizumab
brief summary
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
started
Dec 19, 2025
primary completion
Jun 25, 2027
completion
Jun 25, 2027
last updated
Apr 20, 2026
official title
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol